U.S. Markets closed

Oxford BioMedica PLC (OXB.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
8.46-0.04 (-0.47%)
At close: 4:35PM BST
Full screen
Previous Close8.50
Open8.50
Bid8.25 x 2513500
Ask9.30 x 11600000
Day's Range8.27 - 8.72
52 Week Range2.98 - 11.50
Volume2,781,508
Avg. Volume10,044,349
Market Cap260.93M
Beta-1.29
PE Ratio (TTM)-14.10
EPS (TTM)-0.6
Earnings DateSep 11, 2017 - Sep 15, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.93
  • Reuters16 days ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

  • GlobeNewswirelast month

    Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019

    Oxford BioMedica plc, a leading gene and cell therapy group, notes that the US Food and Drug Administration has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review the CTL019 ...

  • We're sorry this is all we were able to find about this topic.